Athenex is a biotechnology & medical research business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 269 staff and has a trailing 12-month revenue of around $102.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.01 |
|---|---|
| 52-week range | $0.00 - $0.01 |
| 50-day moving average | $0.95 |
| 200-day moving average | $3.35 |
| Wall St. target price | $2.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-10.45 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0061 from 2023-07-26
| 1 week (2024-07-16) | N/A |
|---|---|
| 1 month (2024-06-23) | N/A |
| 3 months (2024-04-23) | N/A |
| 6 months (2024-01-23) | N/A |
| 1 year (2023-07-26) | 0.0061 |
|---|---|
| 2 years (2022-07-27) | -98.86% |
| 3 years (2021-07-27) | 3.69 |
| 5 years (2019-07-26) | 18.64 |
| Revenue TTM | $102.8 million |
|---|---|
| Gross profit TTM | $26.7 million |
| Return on assets TTM | -19.65% |
| Return on equity TTM | -1927.27% |
| Profit margin | -100.59% |
| Book value | $-0.75 |
| Market Capitalization | $2.3 million |
TTM: trailing 12 months
We're not expecting Athenex to pay a dividend over the next 12 months.
Athenex's shares were split on a 1:20 basis on 14 February 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Athenex shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Athenex shares which in turn could have impacted Athenex's share price.
Over the last 12 months, Athenex's shares have ranged in value from as little as $0.0022 up to $0.0061. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 1.3452. This would suggest that Athenex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.